Gastric mucosal distribution and clinical efficacy of azithromycin in patients with Helicobacter pylori related gastritis

Journal of Antimicrobial Chemotherapy

Volumn 42, Issue 1, 1998, Pages 75-82

  Blandizzi, Corrado ^a   Malizia, Tecla ^b   Gherardi, Giorgio ^c   Costa, Francesco ^d   Marchi, Santino ^d   Marveggio, Cristina ^c   Natale, Gianfranco ^b   Senesi, Sonia ^b   Bellini, Massimo ^d   Maltinti, Giacomo ^d   Campa, Mario ^b   Del Tacca, Mario ^a,b  

^a Dipartimento di Medicina Interna   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c Ospedale di Sondrio   (Italy)

^d Istituto di Clinica Medica II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; OMEPRAZOLE; UREASE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TISSUE LEVEL; DUODENUM ULCER; FEMALE; GASTRITIS; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; MALE; ORAL DRUG ADMINISTRATION; STOMACH BIOPSY; STOMACH MUCOSA; ULCER HEALING;

ADULT; AGED; AZITHROMYCIN; DRUG THERAPY, COMBINATION; DUODENAL ULCER; ENDOSCOPY; FEMALE; GASTRIC MUCOSA; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; TREATMENT OUTCOME;

EID: 14444268276     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/42.1.75     Document Type: Article

References (40)

1. Eaton, K. A. & Krakowka. S. (1994). Effect of gastric pH on urease-dependent colonisation of gnotobiotic piglets by Helicobacter pylori. Infectivology and Immunology 62, 3604-7.
2. Sipponen, P. & Hyvarinen, H. (1993). Role of Helicobacter pylori in the pathogenesis of gastritis, peptic ulcer and gastric cancer. Scandinavian Journal of Gastroenterology 28, Suppl. 196, 3-6.
3. Labenz, J. & Borsch, G. (1994). Evidence for the essential role of Helicobacter pylori in gastric ulcer disease. Gut 35, 19-22.
4. Rauws, E. A. J., Langenberg, W., Houthoff, H. J., Zanen, H. C. & Tytgat, G. N. J. (1988). Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment. Gastroenterology 94, 33-40.
5. Tytgat, G. N. J. (1994). Treatments that impact favourably upon eradication of Helicobacter pylori and ulcer recurrence. Alimentary Pharmacology and Therapeutics 8, 359-68.
6. Walsh, J. H. & Peterson, W. L. (1995). The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. New England Journal of Medicine 333, 984-91.
7. Chiba, N., Rao, B. V., Rademaker, J. W. & Hunt, R. H. (1992). Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. American Journal of Gastroenterology 87, 1716-27.
8. Rauws, E. A. J. & Van der Hulst, R. W. M. (1996). Current guidelines for eradication of Helicobacter pylori in peptic ulcer disease. Drugs 50, 984-90.
9. Peters, D. A., Friedel, H. A. & McTavish, D. (1992). Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 44, 750-99.
10. Foulds, G. & Johnson, R. B. (1993). Selection of dose regimen of azithromycin. Journal of Antimicrobial Chemotherapy 31, Suppl. E, 39-50.
11. Kitzis, M. D., Goldstein, F. W., Miegi, M. & Acar, J. F. (1990). In-vitro activity of azithromycin against various Gram-negative bacilli and anaerobic bacteria. Journal of Antimicrobial Chemotherapy 25, Suppl. A, 15-18.
12. Marelli, P., Cellini, L., Campa, M., Dainelli, B., Soldani, G. & Del Tacca, M. (1992). In vitro susceptibility of Helicobacter pylori to macrolides. Irish Journal of Medical Sciences 161, Suppl. 10, 99.
13. Burette, A. & Glupczynski, Y. (1995). Helicobacter pylori: the place of the new macrolides in the eradication of bacteria in peptic ulcer disease, Infection 23, Suppl. 1, S44-52.
14. Malizia, T., Tejada, M., Marchetti, F., Favini, P., Pizzarelli, G., Senesi, S. et al. (1998). Synergistic interactions of macrolides and proton pump inhibitors against Helicobacter pylori: a comparative in-vitro study. Journal of Antimicrobial Chemotherapy 41, Suppl. B, 29-35.
15. Bertoni, G., Sassatelli, R., Nigrisoli, E., Tansini, P., Bianchi, G., Della Casa, G. et al. (1996). Triple therapy with azithromycin, omeprazole, amoxicillin is highly effective in the eradication of Helicobacter pylori: A controlled trial versus omeprazole plus amoxicillin. American Journal of Gastroenterology 91, 258-63.
16. Caselli, M., Ruina, M., Fabbri, P., Balhous, W. & Alvisi, V. (1996). A comparative trial of short term therapy with omeprazole plus either amoxicillin and azithromycin for Helicobacter pylori eradication. Journal of Antimicrobial Chemotherapy 37, 849-50.
17. Malizia, T., Tejada, M. R., Ghelardi, E., Senesi, S., Gabriele, M., Giuca, M. R. et al. (1997). Periodontal tissue disposition of azithromycin. Journal of Periodontology 68, 1206-9.
18. Bianchi Porro, G., Parente, F. & Lazzaroni, M. (1993). Short and long term outcome of Helicobacter pylori positive resistant duodenal ulcers treated with colloidal bismuth plus antibiotic or sucralphate alone. Gut 34, 466-9.
19. Price, A. B. (1991). The Sydney system: histological division. Journal of Gastroenterology and Hepatology 6, 209-22.
20. Malfertheiner, P. (1993). Compliance, adverse events, and antimicrobic resistance in the Helicobacter pylori treatment. Scandinavian Journal of Gastroenterology 28, Suppl. 196, 34-7.
21. Goddard, A. F. & Logan, R. P. H. (1996). Antimicrobial resistance and Helicobacter pylori. Journal of Antimicrobial Chemotherapy 37, 639-43.
22. Lode, H., Borner, K., Koeppe, P. & Schaberg, T. (1996). Azithromycin - review of key chemical, pharmacokinetic and microbiological features. Journal of Antimicrobial Chemotherapy 37, Suppl. C, 1-8.
23. Harrison, J. D., Jones, J. A. & Morris, D. L (1991). Azithromycin levels in plasma and gastric tissue, juice and mucus. European Journal of Clinical Microbiology and Infectious Diseases 10, 862-4.
24. Gladue, R. P., Bright, G. M., Isaacson, R. E. & Newborg, M. F. (1989). In vivo and in vitro uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release in site of infection. Antimicrobial Agents and Chemotherapy 33, 277-82.
25. Retsema, J. A., Bergeron, J. M., Girard, D., Milisen, W. B. & Girard, A. E. (1993). Preferential concentration of azithromycin in an infected mouse thigh model. Journal of Antimicrobial Chemotherapy 31, Suppl. E, 5-16.
26. Wilde, M. I. & McTavish, D. (1994). Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders. Drugs 48, 91-132.
27. Blandizzi, C., Gherardi, G., Marveggio, C., Natale, G., Carignani, D. & Del Tacca, M. (1995). Mechanisms of protection by omeprazole against experimental gastric mucosal damage in rats. Digestion 56, 220-9.
28. Iwahi, T., Satoh, H. & Nakao, M. (1991). Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrobial Agents and Chemotherapy 35, 490-6.
29. 2 antagonists. Digestive Disease Sciences 36, 25-8.
30. Hunt, R. H. (1993). pH and Hp. Gastric acid secretion and Helicobacter pylori: implication for ulcer healing and eradication of the organism. American Journal of Gastroenterology 88, 481-3.
31. Fiese, E. F. & Steffen, S. H. (1990). Comparison of the acid stability of azithromycin and erythromycin A. Journal of Antimicrobial Chemotherapy 25, Suppl. A, 39-47.
32. Hardy, D. J., Hanson, C. W., Hensey, D. M., Beyer, J. M. & Fernandes, P. B. (1988). Susceptibility of Campylobacter pylori to macrolides and fluoroquinolones. Journal of Antimicrobial Chemotherapy 22, 631-6.
33. Malanoski, G. J., Eliopuolos, G. M., Ferraro, M. J. & Moellering, R. C. (1993). Effect of pH variation on the susceptibility of Helicobacter pylori to three macrolide antimicrobial agents and temafloxacin. European Journal of Clinical Microbiology and Infectious Diseases 12, 131-3.
34. Pilotto, A., Franceschi, M., Di Mario, F., Battaglia, G., Bozzola, L., Scagnelli M. et al. (1994). Azithromycin plus omeprazole vs clarithromycin plus omeprazole for the eradication of Helicobacter pylori in elderly. Gut 35, Suppl. 4, A146.
35. Di Mario, F., Dal Bò, N., Grassi, S. A., Rugge, M., Cassaro, M., Donis, P. M. et al. (1996). Azithromycin for the cure of the Helicobacter pylori infection. American Journal of Gastroenterology 91, 264-7.
36. Tursi, A., Cammarota, G., Montalto, M., Papa, A., Fedeli, G. & Gasbarrini, G. (1996). The use of azithromycin in short-term low-dose triple therapies for Helicobacter pylori infection. American Journal of Gastroenterology 91, 817-8.
37. Atherton, J. C., Cockayne, C. J., Balsitis, M., Kirk, G. E., Hawkey, C. J. & Spiller, R. C. (1995). Detection of the intragastric sites at which Helicobacter pylori evades treatment with amoxicillin and cimetidine. Gut 36, 670-4.
38. Bode, G., Malfertheiner, P. & Ditschuneit, H. (1988). Pathogenetic implications of ultrastructural findings in Campylobacter pylori-related gastroduodenal disease. Scandinavian Journal of Gastroenterology 23, Suppl. 142, 25-39.
39. Glupczynski, Y. & Burette, A. (1990). Failure of azithromycin to eradicate Campylobacter pylori from stomach because of acquired resistance during treatment. American Journal of Gastroenterology 85, 98-9.
40. Versalovic, J., Kibler, K., Shall, S., Hachem, C. Y., Graham, D. Y. & Go, M. F. (1995). Molecular basis of clarithromycin resistance in Helicobacter pylori. Gastroenterology 108, A251.